The Impact of the CYP2D6 "Enhancer" Single Nucleotide Polymorphism on CYP2D6 Activity
rs5758550 has been associated with enhanced transcription and suggested to be a useful marker of CYP2D6 activity. As there are limited and inconsistent data regarding the utility of this distant "enhancer" single nucleotide polymorphism (SNP), our goal was to further assess the impact of r...
Uloženo v:
| Vydáno v: | Clinical pharmacology and therapeutics Ročník 111; číslo 3; s. 646 |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
01.03.2022
|
| Témata: | |
| ISSN: | 1532-6535, 1532-6535 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | rs5758550 has been associated with enhanced transcription and suggested to be a useful marker of CYP2D6 activity. As there are limited and inconsistent data regarding the utility of this distant "enhancer" single nucleotide polymorphism (SNP), our goal was to further assess the impact of rs5758550 on CYP2D6 activity toward two probe substrates, atomoxetine (ATX) and dextromethorphan (DM), using in vivo urinary metabolite (DM; n = 188) and pharmacokinetic (ATX; n = 70) and in vitro metabolite formation (ATX and DM; n = 166) data. All subjects and tissues were extensively genotyped, the "enhancer" SNP phased with established CYP2D6 haplotypes either computationally or experimentally, and the impact on CYP2D6 activity investigated using several linear models of varying complexity to determine the proportion of variability in CYP2D6 activity captured by each model. For all datasets and models, the "enhancer" SNP had no or only a modest impact on CYP2D6 activity prediction. An increased effect, when present, was more pronounced for ATX than DM suggesting potential substate-dependency. In addition, CYP2D6*2 alleles with the "enhancer" SNP were associated with modestly higher metabolite formation rates in vitro, but not in vivo; no effect was detected for CYP2D6*1 alleles with "enhancer" SNP. In summary, it remains inconclusive whether the small effects detected in this investigation are indeed caused by the "enhancer" SNP or are rather due to its incomplete linkage with other variants within the gene. Taken together, there does not appear to be sufficient evidence to warrant the "enhancer" SNP be included in clinical CYP2D6 pharmacogenetic testing. |
|---|---|
| AbstractList | rs5758550 has been associated with enhanced transcription and suggested to be a useful marker of CYP2D6 activity. As there are limited and inconsistent data regarding the utility of this distant "enhancer" single nucleotide polymorphism (SNP), our goal was to further assess the impact of rs5758550 on CYP2D6 activity toward two probe substrates, atomoxetine (ATX) and dextromethorphan (DM), using in vivo urinary metabolite (DM; n = 188) and pharmacokinetic (ATX; n = 70) and in vitro metabolite formation (ATX and DM; n = 166) data. All subjects and tissues were extensively genotyped, the "enhancer" SNP phased with established CYP2D6 haplotypes either computationally or experimentally, and the impact on CYP2D6 activity investigated using several linear models of varying complexity to determine the proportion of variability in CYP2D6 activity captured by each model. For all datasets and models, the "enhancer" SNP had no or only a modest impact on CYP2D6 activity prediction. An increased effect, when present, was more pronounced for ATX than DM suggesting potential substate-dependency. In addition, CYP2D6*2 alleles with the "enhancer" SNP were associated with modestly higher metabolite formation rates in vitro, but not in vivo; no effect was detected for CYP2D6*1 alleles with "enhancer" SNP. In summary, it remains inconclusive whether the small effects detected in this investigation are indeed caused by the "enhancer" SNP or are rather due to its incomplete linkage with other variants within the gene. Taken together, there does not appear to be sufficient evidence to warrant the "enhancer" SNP be included in clinical CYP2D6 pharmacogenetic testing.rs5758550 has been associated with enhanced transcription and suggested to be a useful marker of CYP2D6 activity. As there are limited and inconsistent data regarding the utility of this distant "enhancer" single nucleotide polymorphism (SNP), our goal was to further assess the impact of rs5758550 on CYP2D6 activity toward two probe substrates, atomoxetine (ATX) and dextromethorphan (DM), using in vivo urinary metabolite (DM; n = 188) and pharmacokinetic (ATX; n = 70) and in vitro metabolite formation (ATX and DM; n = 166) data. All subjects and tissues were extensively genotyped, the "enhancer" SNP phased with established CYP2D6 haplotypes either computationally or experimentally, and the impact on CYP2D6 activity investigated using several linear models of varying complexity to determine the proportion of variability in CYP2D6 activity captured by each model. For all datasets and models, the "enhancer" SNP had no or only a modest impact on CYP2D6 activity prediction. An increased effect, when present, was more pronounced for ATX than DM suggesting potential substate-dependency. In addition, CYP2D6*2 alleles with the "enhancer" SNP were associated with modestly higher metabolite formation rates in vitro, but not in vivo; no effect was detected for CYP2D6*1 alleles with "enhancer" SNP. In summary, it remains inconclusive whether the small effects detected in this investigation are indeed caused by the "enhancer" SNP or are rather due to its incomplete linkage with other variants within the gene. Taken together, there does not appear to be sufficient evidence to warrant the "enhancer" SNP be included in clinical CYP2D6 pharmacogenetic testing. rs5758550 has been associated with enhanced transcription and suggested to be a useful marker of CYP2D6 activity. As there are limited and inconsistent data regarding the utility of this distant "enhancer" single nucleotide polymorphism (SNP), our goal was to further assess the impact of rs5758550 on CYP2D6 activity toward two probe substrates, atomoxetine (ATX) and dextromethorphan (DM), using in vivo urinary metabolite (DM; n = 188) and pharmacokinetic (ATX; n = 70) and in vitro metabolite formation (ATX and DM; n = 166) data. All subjects and tissues were extensively genotyped, the "enhancer" SNP phased with established CYP2D6 haplotypes either computationally or experimentally, and the impact on CYP2D6 activity investigated using several linear models of varying complexity to determine the proportion of variability in CYP2D6 activity captured by each model. For all datasets and models, the "enhancer" SNP had no or only a modest impact on CYP2D6 activity prediction. An increased effect, when present, was more pronounced for ATX than DM suggesting potential substate-dependency. In addition, CYP2D6*2 alleles with the "enhancer" SNP were associated with modestly higher metabolite formation rates in vitro, but not in vivo; no effect was detected for CYP2D6*1 alleles with "enhancer" SNP. In summary, it remains inconclusive whether the small effects detected in this investigation are indeed caused by the "enhancer" SNP or are rather due to its incomplete linkage with other variants within the gene. Taken together, there does not appear to be sufficient evidence to warrant the "enhancer" SNP be included in clinical CYP2D6 pharmacogenetic testing. |
| Author | Gaedigk, Roger Wang, Wendy Y Boone, Erin C Pearce, Robin E Leeder, James Steven Dinh, Jean C Staggs, Vincent S Gaedigk, Andrea |
| Author_xml | – sequence: 1 givenname: Jean C surname: Dinh fullname: Dinh, Jean C organization: Division of Clinical Pharmacology, Toxicology, and Therapeutic Innovation, Children's Mercy Kansas City, Kansas City, Missouri, USA – sequence: 2 givenname: Erin C surname: Boone fullname: Boone, Erin C organization: Division of Clinical Pharmacology, Toxicology, and Therapeutic Innovation, Children's Mercy Kansas City, Kansas City, Missouri, USA – sequence: 3 givenname: Vincent S surname: Staggs fullname: Staggs, Vincent S organization: Department of Pediatrics, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA – sequence: 4 givenname: Robin E surname: Pearce fullname: Pearce, Robin E organization: Division of Clinical Pharmacology, Toxicology, and Therapeutic Innovation, Children's Mercy Kansas City, Kansas City, Missouri, USA – sequence: 5 givenname: Wendy Y surname: Wang fullname: Wang, Wendy Y organization: Division of Clinical Pharmacology, Toxicology, and Therapeutic Innovation, Children's Mercy Kansas City, Kansas City, Missouri, USA – sequence: 6 givenname: Roger surname: Gaedigk fullname: Gaedigk, Roger organization: Division of Clinical Pharmacology, Toxicology, and Therapeutic Innovation, Children's Mercy Kansas City, Kansas City, Missouri, USA – sequence: 7 givenname: James Steven surname: Leeder fullname: Leeder, James Steven organization: Department of Pediatrics, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA – sequence: 8 givenname: Andrea surname: Gaedigk fullname: Gaedigk, Andrea organization: Department of Pediatrics, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34716917$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkEtLAzEcxINU7EPBTyChJy9bk2weu8dSqxaKFmwPnpZs8l8b2U3WfQj99hZswdPMwG_mMGM08MEDQreUzCgh7MHU3YxxmV6gERUxi6SIxeCfH6Jx234RQniaJFdoGHNFZUrVCO22e8Crqtamw6HA3TEtPjbsUeLp0u-1N9BM8bvznyXg196UEDpnAW9CeahCU-9dW-Hgz5256dyP6w7X6LLQZQs3J52g3dNyu3iJ1m_Pq8V8HRlOSRpRnSdScq4VTVKeiLyw1pLEyEJRlVsDkjCwWhRGEckMVwTACpKDVTHw3LAJuv_brZvw3UPbZZVrDZSl9hD6NmMiJTSWgogjendC-7wCm9WNq3RzyM5XsF_P_19M |
| CitedBy_id | crossref_primary_10_3389_fgene_2023_1187415 crossref_primary_10_1186_s12864_025_11374_7 crossref_primary_10_1007_s00228_024_03721_6 crossref_primary_10_1002_cpt_3044 crossref_primary_10_3389_fphar_2023_1186540 |
| ContentType | Journal Article |
| Copyright | 2021 The Authors. Clinical Pharmacology & Therapeutics © 2021 American Society for Clinical Pharmacology and Therapeutics. |
| Copyright_xml | – notice: 2021 The Authors. Clinical Pharmacology & Therapeutics © 2021 American Society for Clinical Pharmacology and Therapeutics. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1002/cpt.2469 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1532-6535 |
| ExternalDocumentID | 34716917 |
| Genre | Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NLM NIH HHS grantid: HHSN267200700004G – fundername: NIDDK NIH HHS grantid: HHSN267200700004C – fundername: NLM NIH HHS grantid: HHSN276201200017C – fundername: NICHD NIH HHS grantid: P50 HD090258 – fundername: NICHD NIH HHS grantid: R01 HD058556 |
| GroupedDBID | --- --K -Q- .55 .GJ 0R~ 1B1 1CY 1OB 1OC 29B 33P 354 36B 39C 3O- 4.4 52O 53G 5GY 5RE 6J9 70F 8F7 AAESR AAHQN AAIPD AAKAS AAMMB AAMNL AANHP AANLZ AAONW AAQOH AAQQT AAWTL AAYCA AAZKR ABCUV ABJNI ABLJU ABQWH ACBNA ACBWZ ACCZN ACGFO ACGFS ACGOF ACPOU ACRPL ACXQS ACYXJ ADBBV ADBTR ADKYN ADNMO ADXAS ADZCM ADZMN AEFGJ AEGXH AEIGN AENEX AEUYR AEYWJ AFBPY AFFNX AFFPM AGHNM AGQPQ AGXDD AGYGG AHBTC AI. AIAGR AIDQK AIDYY AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMYDB ASPBG AVWKF AZFZN AZVAB BDRZF BFHJK BMXJE BRXPI C45 CAG CGR COF CS3 CUY CVF DCZOG DPXWK DU5 EBS ECM EE. EIF EJD EMOBN F5P GODZA GWYGA HGLYW IH2 IHE J5H L7B LATKE LEEKS LITHE LOXES LSO LUTES LYRES M41 MEWTI N4W N9A NPM NQ- O9- OPC OVD P2P P2W PALCI RIG RIWAO RJQFR RNTTT ROL RPZ SAMSI SEW SJN SUPJJ TEORI TWZ UHS VH1 WBKPD WH7 WOHZO WXSBR X7M Y6R YFH YOC YXB ZGI ZXP ZZTAW 7X8 |
| ID | FETCH-LOGICAL-c4109-1ab86644a7189485bfddd08c6f717bdce602eda5fc7062c470eed50bed73e4bc2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 6 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000724029500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1532-6535 |
| IngestDate | Wed Jul 30 10:26:53 EDT 2025 Mon Jul 21 06:03:16 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Language | English |
| License | 2021 The Authors. Clinical Pharmacology & Therapeutics © 2021 American Society for Clinical Pharmacology and Therapeutics. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4109-1ab86644a7189485bfddd08c6f717bdce602eda5fc7062c470eed50bed73e4bc2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/8825689 |
| PMID | 34716917 |
| PQID | 2590136505 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2590136505 pubmed_primary_34716917 |
| PublicationCentury | 2000 |
| PublicationDate | March 2022 |
| PublicationDateYYYYMMDD | 2022-03-01 |
| PublicationDate_xml | – month: 03 year: 2022 text: March 2022 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Clinical pharmacology and therapeutics |
| PublicationTitleAlternate | Clin Pharmacol Ther |
| PublicationYear | 2022 |
| SSID | ssj0004988 |
| Score | 2.4111955 |
| Snippet | rs5758550 has been associated with enhanced transcription and suggested to be a useful marker of CYP2D6 activity. As there are limited and inconsistent data... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 646 |
| SubjectTerms | Adolescent Alleles Atomoxetine Hydrochloride - therapeutic use Child Cytochrome P-450 CYP2D6 - genetics Dextromethorphan - therapeutic use Genotype Haplotypes - genetics Humans Pharmacogenomic Testing - methods Phenotype Polymorphism, Single Nucleotide - genetics |
| Title | The Impact of the CYP2D6 "Enhancer" Single Nucleotide Polymorphism on CYP2D6 Activity |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/34716917 https://www.proquest.com/docview/2590136505 |
| Volume | 111 |
| WOSCitedRecordID | wos000724029500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bS8MwGA3qfPDF-2XeiEP2tLouTdP2ScbcUNBScIP5VHIrDrZ2rlPYvzdJW-aTCL70pQRC8iXfSb6ccwC4VRCcUeQTC7uJow4oAlss8LmFKPWprmMJZojCz14Y-uNxEJUXbnn5rLLaE81GLTKu78jbSJMkHYUn3Pv5h6Vdo3R1tbTQ2AQ1R0EZHdXe-IdaeGB8J9WiRhZxHbcSn7VRm8-XdwiTX4ClSTCDvf92bR_sltASdotYOAAbMj0EzajQpl614HBNtcpbsAmjtWr16giM1G_4ZDiTMEugwoWw9xahBwIb_fRdx8aiAV9VoptKGGoR5Gw5ERJG2XQ1y9RkTfIZzNKqTZcXrhTHYDToD3uPVum5YHHc0c4IlPlEYSSqcpYWjmGJEML2OUnUuY8JLomNpKBuwj2bII49WyVZ12ZSeI7EjKMTsJVmqTwD0A8Sm1EiPD9gGEseCCSYR1iHSSOkVwc31XDGKqZ1oYKmMvvM4_WA1sFpMSfxvBDfiB1s9H288z-0vgA7SLMVzJOxS1BL1IqWV2Cbfy0n-eLaBIv6htHLNxn2yWc |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Impact+of+the+CYP2D6+%22Enhancer%22+Single+Nucleotide+Polymorphism+on+CYP2D6+Activity&rft.jtitle=Clinical+pharmacology+and+therapeutics&rft.au=Dinh%2C+Jean+C&rft.au=Boone%2C+Erin+C&rft.au=Staggs%2C+Vincent+S&rft.au=Pearce%2C+Robin+E&rft.date=2022-03-01&rft.issn=1532-6535&rft.eissn=1532-6535&rft.volume=111&rft.issue=3&rft.spage=646&rft_id=info:doi/10.1002%2Fcpt.2469&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1532-6535&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1532-6535&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1532-6535&client=summon |